Summary
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
History
Immatics was founded in 1996 and has since grown to become a world leader in the research and development of next-generation immunotherapies. Our cutting-edge cancer immunotherapies and other T-cell engaging therapies are tested and developed in close collaboration with leading medical institutions and universities across the globe, providing us with innovative insights into how to best treat and beat cancer.
Mission
To develop and provide precision medicine solutions in the fields of cancer immunotherapy, stimulating and restoring anti-tumor immunity and thus creating new life opportunities for cancer patients.
Vision
To become a global leader in developing precision medicines that transform the treatment of cancer and other severe diseases.
Key Team
Mr. Arnd Christ MBA (Chief Financial Officer)
Mr. Steffen Walter Ph.D. (Chief Technology Officer)
Mr. Edward A. Sturchio (Gen. Counsel & Sec.)
Ms. Anja Heuer B.Sc. (Director of Corp. Communications)
Ms. Tamara Louw M.B.A., P.H.R. (Sr. Director of HR)
Dr. Carsten Reinhardt M.D., Ph.D. (Chief Devel. Officer)
Dr. Rainer Kramer Ph.D. (Chief Bus. Officer & Site Head Munich)
Recognition and Awards
Immatics has been recognised with numerous awards, including being named amongst the ‘top 20 cell therapy companies’ by Global Health Magazine in 2018 and winning the Frost & Sullivan award for Technology Innovation Leadership in 2019.
References
Germany 